tbuckley/cabot-search huggingface dataset:
Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial
Authors: Gideon Amanyire, Fred C Semitala, Jennifer Namusobya, Richard Katuramu, Leatitia Kampiire, Jeanna Wallenta, Edwin Charlebois, Carol Camlin, James Kahn, Wei Chang, David Glidden, Moses Kamya, Diane Havlir, Elvin Geng
Journal: The Lancet HIV (2016)
PTH-139 Long Acting Octreotide Therapy Has A Beneficial Effect In Patients With Significant Small Bowel Angiodysplasia: Abstract PTH-139 Table 1
Authors: G Holleran, B Hall, N Breslin, D McNamara
Journal: Gut (2014)

<h3>Introduction</h3> Angiodysplasias account for up to 50% of causes of small bowel bleeding and due to their relative inaccessibility and the intermittent nature of their bleeding they present a particular therapeutic challenge. Endoscopic ablation with APC is the most efficacious at reducing re-bleeding rates, however; its effect is short-lived and not all small bowel lesions are amenable to treatment via DBE. It has been suggested by a recent small trial that long-acting Octreotide may be beneficial at reducing re-bleeding rates. <h3>Methods</h3> Following ethical approval patients with significant recurrent anaemia (≥6 months with RCC transfusions) and definite small bowel angiodysplasia (P2), on capsule endoscopy were invited to participate in an open label, uncontrolled pilot study of monthly 20 mg long acting Octreotide. Patients who had lesions amenable to APC via DBE were treated prior to commencing Octreotide. Baseline demographics, medications, endoscopy and capsule findings and Hb level were recorded. Patients were assessed at regular intervals and evaluated for side effects and episodes of bleeding (defined as either overt bleeding or a Hb drop of &gt;1 g/dL). Patients who received fewer than three doses were excluded from analysis. <h3>Results</h3> A total of 22 patients, 50% (n = 11) female, mean age of 72 years (range 55–92) have been recruited to date, 16 (73%) with isolated small bowel angiodysplasias and 6 with small bowel and colonic lesions. Of these, 17 (77%) received at least 3 doses, 11 (65%) had DBE and APC prior to commencing Octreotide, and 11 (65%) were on anticoagulants (4 warfarin, 7 aspirin and 2 dual antiplatelet therapy with aspirin and clopidogrel). The mean duration of treatment was 8.1 months (range 3–15). There was a statistically significant difference in mean baseline and follow up Hb levels, 8.7 g/dL (5–11.1) and 11.2 g/dL (8–14.3) respectively, p &lt; 0.001. Overall there were 8 re-bleeding episodes in 5 patients (29%). Prior APC treatment did not affect outcome (Table 1). Significant side effects occurred in 3 patients (13.6%), 1 allergic skin reaction, 1 thrombocytopenia and 1 choledocholithiasis. <h3>Conclusion</h3> Our study has shown that long acting intramuscular Octreotide is effective at improving Hb levels in patients with refractory small bowel angiodysplasias. A longer follow up interval will be required to determine the beneficial effect of combination therapy. We have identified a relatively high rate of serious side effects, in contrast to previous reports, which need to be taken into consideration prior to commencing treatment. <h3>Disclosure of Interest</h3> None Declared.
Brazil to investigate if other factors act with Zika to cause congenital defects
Authors: Cláudia Collucci
Journal: BMJ (2016)

The Brazilian government has launched an investigation to find out if factors other than Zika virus disease were involved in the development of microcephaly in some fetuses after noting an uneven distribution of cases across the country.

In spring this year the WHO and the US Centers for Disease Control and Prevention announced that Zika infection during pregnancy was linked with microcephaly as well as congenital blindness, stillbirth, and other fetal abnormalities.1 2 The acknowledgement came a year after the first case of Zika infection was confirmed in Brazil.3

But scientists in Brazil have been puzzled by the fact that cases of congenital Zika syndrome have clustered in the north east part of the country, and that the expected surge …
Fecundity after childhood cancer: A nationwide, population-based study.
Authors: M. Cvancarova, M. R. Forman, S. D. Fossa
Journal: Journal of Clinical Oncology (2010)

1574 Background: Despite improved fertility-preserving treatment, reproductive rates in childhood cancer survivors are expected to be lower than in the general population. Methods: We investigated reproductive patterns in 4,713 childhood cancer survivors of the most common diagnoses and 23,630 age- and gender- matched controls using data from the Cancer and the Medical Birth Registry of Norway. All were born ≥ 1951 and diagnosed with cancer 1953-2004, at age 0-16 yrs (median 5). Follow-up was from the date of diagnosis for pts, assigned date for controls, until first pregnancy after cancer (regardless the outcome), emigration, death or Dec 31, 2008.Competing risk regression models were used to compute overall reproductive rates for both genders, and separately for each of the selected diagnoses. The hazard rates (SHRs) were adjusted for age at diagnosis and computed for pts diagnosed 1980+. Results: Overall, males were 72% less likely to initiate a pregnancy compared to their age-matched controls (SHR=0.28 [0.25-0.31]). For females the rates were slightly more favorable, the pts were 62% less likely to become pregnant (SHR=0.38 [ 0.34-0.42]). Pts treated 1980+ were more likely to experience a pregnancy than those diagnosed before, twice as likely for females: 0.22 vs 0.55. For males, the difference was even higher: 0.17 vs. 0.45 (SHR for <1980 given first). The most remarkable improvement was seen for survivors of leukemia. Conclusions: This population-based study revealed lower overall fecundity in cancer survivors than in the general population, but there has been a remarkable improvement for survivors diagnosed 1980+, more so for the female patients. < 1980 1980+ F M F M Leukemia 0.12 [0.09-0.16] 0.07 [0.05-0.10] 0.57 [0.42-0.76] 0.51 [0.38- 0.69] Eye 0.39 [0.24-0.66] 0.75 [0.50-1.12] 0.56 [0.19-1.63] 0.39 [0.15-0.98] CNS 0.17 [0.12-0.23] 0.16 [0.12-0.21] 0.47 [0.34-0.63] 0.29 [0.20-0.43] Kidney 0.37 [0.23-0.59] 0.45 [0.30-0.65] 0.47 [0.22- 1.00] 0.87 [0.41-1.83] Mal. lymphoma 0.44 [0.29-0.67] 0.23 [0.15-0.34] 0.62 [0.44- 0.88] 0.42 [0.28-0.61] Bone and soft tissue 0.41 [0.26- 0.64] 0.30 [0.17-0.52] 0.69 [0.47-1.00] 1.03 [0.63-1.67] * Ref = controls [95% CI]. No significant financial relationships to disclose.
Abstract POSTER-BIOL-1303: ARID3B alters tumor cell adhesion by binding to the promoter regions in fzd5 and other wnt pathway genes
Authors: Alexander Bobbs, William Morgan Hallas, Katrina Gellerman, Stancy Joseph, Karen Cowden Dahl
Journal: Clinical Cancer Research (2015)

Abstract ARID3B is a DNA-binding protein from the AT-rich interactive domain family that is overexpressed in ovarian cancer and promotes tumor progression in a xenograft model of ovarian cancer in nude mice. Prior to this study, direct ARID3B target genes had not been identified, and relatively little was known about ARID3B's function or consensus binding site. In this study, we identified and confirmed the first gene targets of ARID3B by chromatin immunoprecipitation, microarray, and quantitative real-time PCR. Based on the binding sites that were determined in this study, we defined a novel ARID3B binding site that was tested in an electrophoretic mobility shift assay. Analysis of ARID3B binding regions revealed that ARID3B regulates genes in key cellular pathways that are involved in cancer progression and drug resistance, including EGFR, NOTCH, TNF, centromere proteins, and the Wnt signaling pathway. We have focused on Wnt signaling, and showed that ARID3B binds to the promoter regions of Wnt5A and its receptor FZD5, along with downstream components of the pathway: APC and MYC. FZD5 is commonly over-expressed in ovarian cancer cell lines, and is further upregulated by excess ARID3B. Upregulation of either ARID3B or FZD5 increased adhesion to extra-cellular matrix components Collagen IV, Fibronectin, Laminin, Tenascin, and Vitronectin. These results establish that Wnt signaling is targeted by ARID3B, and provide key insights into how ARID3B affects tumor progression. Citation Format: Alexander Bobbs, William Morgan Hallas, Katrina Gellerman, Stancy Joseph Karen Cowden Dahl. ARID3B alters tumor cell adhesion by binding to the promoter regions in fzd5 and other wnt pathway genes [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-BIOL-1303.
Antiviral Agents Added to Corticosteroids for Early Treatment of Adults With Acute Idiopathic Facial Nerve Paralysis (Bell Palsy)
Authors: Frank Sullivan, Fergus Daly, Ildiko Gagyor
Journal: JAMA (2016)

<h3>Clinical Question</h3> Compared with oral corticosteroids alone, are oral antiviral drugs associated with improved outcomes when combined with oral corticosteroids in patients presenting within 72 hours of the onset of Bell palsy? <h3>Bottom Line</h3> Compared with oral corticosteroids alone, the addition of acyclovir, valacyclovir, or famcyclovir to oral corticosteroids for treatment of Bell palsy was associated with a higher proportion of people who recovered at 3- to 12-month follow-up. The quality of evidence is limited by heterogeneity, imprecision of the result estimates, and risk of bias.
mRNA expression of protein phosphatase 2A/C (PP2A/C) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
Authors: T. Moran, C. Costa, A. Gimenez Capitan, E. Carcereny, B. Massuti, M. Provencio, J. Wei, S. Benlloch, M. Taron, R. Rosell
Journal: Journal of Clinical Oncology (2010)

e18037 Background: EGFR mutations can influence double-strand break (DSB) repair due to impairment of DNA-PKcs/Ku complexes. PP2A enhances Ku and DNA-PK activities, accelerating DSB repair. In addition, erlotinib causes DSBs in breast cancer cell lines and depletion of nuclear BRCA1 increases erlotinib cytotoxicity. Methods: We examined PP2A/C expression by QPCR in the original pretreatment tumor biopsies of 96 stage IV NSCLC p with EGFR mutations, in whom BRCA1 expression levels and the T790M mutation had previously been assessed. Expression levels by terciles were correlated with outcome to erlotinib. Results: No differences were observed in PP2A/C expression according to gender, smoking history, PS, type of EGFR mutation, or other clinical characteristics. Overall response rate (RR) was 70%, progression-free survival (PFS) was 14 months (m), and median survival (MS) was 27 m. RR was 76.7% for p in the lowest tercile of PP2A/C expression, 60% in the intermediate tercile and 70.4% in the highest tercile (p = 0.37). PFS was 18, 19 and 11 m, respectively (p = 0.22). MS was 33, 36 and 29 m, respectively (p = 0.31). There was no correlation between BRCA1 and PP2A/C levels (r = 0.161; p = 0.16). In a multivariate analysis including the baseline EGFR T790M mutation and BRCA1 levels, PP2A/C was an independent prognostic factor for PFS (intermediate tercile HR, 2.62; p = 0.03; highest tercile HR, 3.25; p = 0.007). Conclusions: PP2A/C is involved in nonhomologous end-joining repair. PP2A/C mRNA levels examined by QPCR could predict the PFS interval to erlotinib in patients with EGFR mutations. No significant financial relationships to disclose.
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
Authors: Li Zhang, Yan Huang, Shaodong Hong, Yunpeng Yang, Gengsheng Yu, Jun Jia, Peijian Peng, Xuan Wu, Qing Lin, Xuping Xi, Jiewen Peng, Mingjun Xu, Dongping Chen, Xiaojun Lu, Rensheng Wang, Xiaolong Cao, Xiaozhong Chen, Zhixiong Lin, Jianping Xiong, Qin Lin, Conghua Xie, Zhihua Li, Jianji Pan, Jingao Li, Shixiu Wu, Yingni Lian, Quanlie Yang, Chong Zhao
Journal: The Lancet (2016)
Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma
Authors: Marie-Helene Delfau-Larue, Isabelle Nel, Axel VAN Der Gucht, Gaelle Laboure, Benjamin Verret, Salma Hamdane, Philippe Gaulard, Michel Meignan, Corinne Haioun, Christiane Copie-Bergman, Jehan Dupuis, Emmanuel Itti
Journal: Blood (2015)
CD1a on Langerhans cells controls inflammatory skin disease
Authors: Ji Hyung Kim, Yu Hu, Tang Yongqing, Jessica Kim, Victoria A Hughes, Jérôme Le Nours, Elsa A Marquez, Anthony W Purcell, Qi Wan, Masahiko Sugita, Jamie Rossjohn, Florian Winau
Journal: Nature Immunology (2016)
Combination of High Serum Lactate Dehydrogenase Levels at the Time of First Diagnosis and Progression Predicts Early Lymphoma Related Death in Patients with Follicular Lymphoma Receiving R-CHOP Regimen
Authors: Satsuki Murakami, Harumi Kato, Kazuhito Yamamoto, Hirofumi Taji, Yusuke Higuchi, Yasushi Yatabe, Shigeo Nakamura, Tmohiro Kinoshita
Journal: Blood (2014)
Prognostic Variables in Newly Diagnosed Children with Acute Myeloid Leukemia: AML-XH-99.
Authors: Long-Jun Gu, Li-Jun Tie, Jing Chen, Ci Pan, Lu Dong, Hui Ye, Hui-Liang Xue, JingYan Tang, Yao-Ping Wang, Jia-Yin
Journal: Blood (2004)
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
Authors: Helena A. Yu, Leslie Perez, Qing Chang, Sizhi P. Gao, Mark G. Kris, Gregory J. Riely, Jacqueline Bromberg
Journal: Journal of Thoracic Oncology (2016)
Values for ADAMTS-13 Activity, Antigen and Autoantibodies in Normal European Controls.
Authors: Sabine Geiter, Markus Graf, Elin Tschokert, Agnes Veyradier, Martine Wolf, Claudine Caron, Roberta Palla, Flora Peyvandi, Johanna A Kremer Hovinga, Irmela Sulzer, Helga Vetr
Journal: Blood (2009)
Biotechnology Products and University-Based Science
Authors: Gregory K Sobolski
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Costs of Contraceptive Coverage Under the Affordable Care Act
Authors: Nora V. Becker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTK7 Is Involved in the Chemotherapy Resistance of T-Cell Acute Lymphoblastic Leukemia through Interaction with FADD-Death Domain
Authors: Hideki Goto, Rachel Wilkie Grantham, Motoaki Mizuuchi, Tetsuji Yamaguchi, Takanori Teshima, John C. Reed, Shu-ichi Matsuzawa
Journal: Blood (2015)
Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC).
Authors: T. M. Kadia, F. Ravandi Kashani, S. M. O'Brien, J. E. Cortes, E. Jabbour, G. Borthakur, S. Faderl, S. Pierce, M. Brandt, H. Kantarjian
Journal: Journal of Clinical Oncology (2010)

6529 Background: Controversy exists as to how well elderly pts with AML tolerate IC, how to select them for IC vs low intensity regimens, and the benefit for IC. Aims: To define the outcome of elderly pts (age 70+ yrs) with AML who have received IC at MDACC since 1990. Methods: Study Groups and Methods. Pts ≥70 yrs with newly diagnosed AML by WHO criteria (20% or more blasts). IC = regimens containing standard-dose or high-dose cytarabine (APL excluded). Results: 446 pts were treated with IC. Median age 74 yrs (range 70-88). Karyotypes: core binding factor (CBF–inversion 16 or translocation 8;21) –16 (3%), diploid–173 (39%), chromosome 5 or 7 abn ±1 additional abnormality–28 (6%), other non-complex karyotypes (< 3 abn)–94 (21%) and complex karyotypes (3 or more abn; including chromosome 5 or 7 abn)–135 (30%). In 16 p with CBF, 10 (63%) had CR; median survival 15 months (mos). Of the other 430 pts, 193 (45%) achieved CR; median survival 4.6 mos; 3- and 5-yr survival rates 10% and 4%. Of 193 pts achieving CR, median CRD 10.6 mos, 3-yr CRD rate 21%, 3- and 5-yr survival rates 19% and 9%. The 4-week (wk) induction mortality was 26%, the 8-wk mortality 36%. In pts treated before 2000 (n = 264) and since 2000 (n = 166), CR rates were 49% vs 38%, 8-wk mortality rates 39% vs 30%, median survivals 4.4 vs. 4.6 mos. A multivariate analysis selected the following to be independently associated with high 8-wk mortality rates (p < 0.05): age ≥ 80 yrs, complex karyotypes (≥ 3 abn), creatinine > 1.3 mg%, and PS 2-4. Patients with none (28%), 1 (40%), 2 (23%), or 3 or more (9%) adverse factors had 8-wk mortality rates of 16%, 31%, 55%, and 71%. Conclusions: Elderly pts with CBF AML (3%) benefit from IC. In other elderly pts, despite delivering IC and a CR rate of 45%, only a fraction (age < 80 yrs + non-complex karyotype + PS 0-1 + creatinine ≤ 1.3 mg%; 28% of total) can receive IC safely. In most others (69%), IC is associated with 8-wk mortality rates of 31% to 71%. In them, alternative investigational, low-intensity, or targeted therapies are justifiable and must be further explored. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genzyme Genzyme
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Authors: Adil I. Daud, Kimberly Loo, Mariela L. Pauli, Robert Sanchez-Rodriguez, Priscila Munoz Sandoval, Keyon Taravati, Katy Tsai, Adi Nosrati, Lorenzo Nardo, Michael D. Alvarado, Alain P. Algazi, Miguel H. Pampaloni, Iryna V. Lobach, Jimmy Hwang, Robert H. Pierce, Iris K. Gratz, Matthew F. Krummel, Michael D. Rosenblum
Journal: Journal of Clinical Investigation (2016)

Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options.We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype.Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs.Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.
Antepartum Dental Radiography and Low Birth Weight
Authors: Peter B. Lockhart, Michael T. Brennan, Howell Sasser, John Ludlow
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal